Epigenetics, the holy grail in the pathogenesis of systemic sclerosis

Rheumatology (United Kingdom)

Volumn 54, Issue 10, 2015, Pages 1759-1770

  Altorok, Nezam ^a   Almeshal, Nawaf ^a   Wang, Yongqing ^a   Kahaleh, Bashar ^a  

^a UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

Author keywords

DNA methylation; Endothelial cells; Epigenetic; Fibroblasts; Fibrosis; Friend leukaemia integration 1 transcription factor; Histone modifications; MicroRNA; Nitric oxide synthase; Scleroderma

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BONE MORPHOGENETIC PROTEIN 2; CD40 LIGAND; CD70 ANTIGEN; CELL ADHESION MOLECULE; COLLAGEN; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; INTERLEUKIN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHYL CPG BINDING PROTEIN 2; METHYL CPG DNA BINDING PROTEIN 1; METHYL CPG DNA BINDING PROTEIN 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN; PROTEIN P53; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; BLOOD VESSEL INJURY; CAPILLARY ENDOTHELIAL CELL; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COLLAGEN SYNTHESIS; DEMETHYLATION; DENDRITIC CELL; DIET; DNA METHYLATION; DOWN REGULATION; EPIGENETIC REPRESSION; EPIGENETICS; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; HISTONE ACETYLATION; HISTONE CODE; HISTONE MODIFICATION; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; HYPOXIA; INFLAMMATORY CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MYOFIBROBLAST; NONHUMAN; NUTRITION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; UPREGULATION; X CHROMOSOME INACTIVATION;

EID: 84943741049     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu155     Document Type: Review

References (105)

1. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005;26:587-95.
2. Nikpour M, Stevens WM, Herrick AL, Proudman SM. Epidemiology of systemic sclerosis. Best Pract Res Clin Rheumatol 2010;24:857-69.
3. Maricq HR, Weinrich MC, Keil JE et al. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989;32:998-1006.
4. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003;29:239-54.
5. Valesini G, Litta A, Bonavita MS et al. Geographical clustering of scleroderma in a rural area in the province of Rome. Clin Exp Rheumatol 1993;11:41-7.
6. Silman AJ, Howard Y, Hicklin AJ, Black C. Geographical clustering of scleroderma in south and west London. Br J Rheumatol 1990;29:93-6.
7. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
8. Altorok N, Sawalha AH. Epigenetics in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol 2013;25:569-76.
9. Javierre BM, Hernando H, Ballestar E. Environmental triggers and epigenetic deregulation in autoimmune disease. Discov Med 2011;12:535-45.
10. Gu YS, Kong J, Cheema GS et al. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008;38: 132-60.
11. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117: 557-67.
12. Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975;4:351-68.
13. Sgonc R, Gruschwitz MS, Dietrich H et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996;98:785-92.
14. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013;65:1953-62.
15. Mavalia C, Scaletti C, Romagnani P et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997;151:1751-8.
16. Leroy EC. Connective tissue synthesis by scleroderma skin fibroblasts in cell culture. J Exp Med 1972;135: 1351-62.
17. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor beta signalling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 2001;44:474-80.
18. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350-8.
19. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003;48:1964-78.
20. Scharffetter K, Lankat-Buttgereit B, Krieg T. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988;18:9-17.
21. Ihn H, Yamane K, Asano Y, Jinnin M, Tamaki K. Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. Rheumatology 2006; 45:157-65.
22. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 2004; 113:253-64.
23. Kubo M, Czuwara-Ladykowska J, Moussa O et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003;163:571-81.
24. Wei J, Ghosh AK, Sargent JL et al. PPARg downregulation by TGFb in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010;5:e13778.
25. Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003;48: 1956-63.
26. Favalli E, Ingegnoli F, Zeni S, Fare M, Fantini F. [HLA typing in systemic sclerosis]. Reumatismo 2001;53: 210-4.
27. Luo Y, Wang Y, Wang Q, Xiao R, Lu Q. Systemic sclerosis: genetics and epigenetics. J Autoimmun 2013;41:161-7.
28. Agarwal SK, Reveille JD. The genetics of scleroderma (systemic sclerosis). Curr Opin Rheumatol 2010;22: 133-8.
29. Radstake TR, Gorlova O, Rueda B et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010;42:426-9.
30. Rueda B, Broen J, Simeon C et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009;18:2071-7.
31. Ito I, Kawaguchi Y, Kawasaki A et al. Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum 2009; 60:1845-50.
32. Dieude P, Guedj M, WipffJ et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 2009;60:225-33.
33. Reinhart BJ, Slack FJ, Basson M et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000;403:901-6.
34. Richardson B. Primer: epigenetics of autoimmunity. Nat Rev Rheumatol 2007;3:521-7.
35. Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006;54:2271-9.
36. Qi Q, Guo Q, Tan G et al. Predictors of the scleroderma phenotype in fibroblasts from systemic sclerosis patients. J Eur Acad Dermatol Venereol 2009;23:160-8.
37. Fish JE, Marsden PA. Endothelial nitric oxide synthase: insight into cell-specific gene regulation in the vascular endothelium. Cell Mol Life Sci 2006;63:144-62.
38. Romero LI, Zhang DN, Cooke JP et al. Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma. Vasc Med 2000;5:147-58.
39. Huang PL, Huang Z, Mashimo H et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995;377:239-42.
40. Lee PC, Salyapongse AN, Bragdon GA et al. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Physiol 1999;277(4 Pt 2):H1600-8.
41. Wang Y, Kahaleh B. Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma. J Cell Mol Med 2013;17:1291-99.
42. Lei W, Luo Y, Lei W et al. Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand J Rheumatol 2009;38:369-74.
43. Sawalha AH, Jeffries M, Webb R et al. Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun 2008;9:368-78.
44. Sawalha AH, Richardson B. MEK/ERK pathway inhibitors as a treatment for inflammatory arthritis might result in the development of lupus: comment on the article by Thiel et al. Arthritis Rheum 2008;58:1203-4; author reply 4.
45. Singer-Sam J, Riggs AD. X chromosome inactivation and DNA methylation. EXS 1993;64:358-84.
46. Robertson KD. DNA methylation and chromatin - unraveling the tangled web. Oncogene 2002;21: 5361-79.
47. Hellman A, Chess A. Gene body-specific methylation on the active X chromosome. Science 2007;315:1141-3.
48. Miranda TB, Jones PA. DNA methylation: the nuts and bolts of repression. J Cell Physiol 2007;213:384-90.
49. Lyon MF. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 1961;190:372-3.
50. Fukasawa C, Kawaguchi Y, Harigai M et al. Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): role of CD40-CD154 in the phenotype of SSc fibroblasts. Eur J Immunol 2003;33: 2792-800.
51. Lian X, Xiao R, Hu X et al. DNA demethylation of CD40l in CD4+ T cells from women with systemic sclerosis: a possible explanation for female susceptibility. Arthritis Rheum 2012;64:2338-45.
52. Valentini G, Romano MF, Naclerio C et al. Increased expression of CD40 ligand in activated CD4+ T lymphocytes of systemic sclerosis patients. J Autoimmun 2000; 15:61-6.
53. Komura K, Fujimoto M, Yanaba K et al. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Ann Rheum Dis 2008;67:867-72.
54. Selmi C, Feghali-Bostwick CA, Lleo A et al. X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma. Clin Exp Immunol 2012;169:253-62.
55. Jiang H, Xiao R, Lian X et al. Demethylation of TNFSF7 contributes to CD70 overexpression in CD4+ T cells from patients with systemic sclerosis. Clin Immunol 2012;143: 39-44.
56. Wang YS, Shu Y, Wang Q et al. Demethylation of ITGAL (CD11a) Regulatory Sequences in CD4+ T Lymphocytes of Systemic Sclerosis. 2013. Abstract 2905. American College of Rheumatology, San Diego.
57. Kondo Y, Shen L, Cheng AS et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008; 40:741-50.
58. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004;50:1918-27.
59. Wang Y, Yang Y, Luo Y et al. Aberrant histone modification in peripheral blood B cells from patients with systemic sclerosis. Clin Immunol 2013;149:46-54.
60. Kramer M, Dees C, Huang J et al. Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis 2013;72:614-20.
61. Hemmatazad H, Rodrigues HM, Maurer B et al. Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis Rheum 2009;60: 1519-29.
62. Huber LC, Distler JH, Moritz F et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum 2007;56:2755-64.
63. Matouk CC, Marsden PA. Epigenetic regulation of vascular endothelial gene expression. Circ Res 2008;102: 873-87.
64. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
65. Saj A, Lai EC. Control of microRNA biogenesis and transcription by cell signaling pathways. Curr Opin Genet Dev 2011;21:504-10.
66. Suzuki HI, Miyazono K. Emerging complexity of microRNA generation cascades. J Biochem 2011;149:15-25.
67. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010;11:597-610.
68. Vrba L, Garbe JC, Stampfer MR, Futscher BW. Epigenetic regulation of normal human mammary cell type-specific miRNAs. Genome Res 2011;21:2026-37.
69. Tijsen AJ, Pinto YM, Creemers EE. Non-cardiomyocyte microRNAs in heart failure. Cardiovascu Res 2012;93: 573-82.
70. Kato M, Park JT, Natarajan R. MicroRNAs and the glomerulus. Exp Cell Res 2012;318:993-1000.
71. Wang XW, Heegaard NH, Orum H. MicroRNAs in liver disease. Gastroenterology 2012;142:1431-43.
72. Vettori S, Gay S, Distler O. Role of microRNAs in fibrosis. Open Rheumatol J 2012;6:130-9.
73. Nakashima T, Jinnin M, Yamane K et al. Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 2012; 188:3573-83.
74. Makino K, Jinnin M, Hirano A et al. The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma. J Immunol 2013;190:3905-15.
75. Kajihara I, Jinnin M, Yamane K et al. Increased accumulation of extracellular thrombospondin-2 due to low degradation activity stimulates type I collagen expression in scleroderma fibroblasts. Am J Pathol 2012;180: 703-14.
76. Etoh M, Jinnin M, Makino K et al. microRNA-7 downregulation mediates excessive collagen expression in localized scleroderma. Arch Dermatol Res 2013;305: 9-15.
77. Zhu H, Li Y, Qu S et al. MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma. J Clin Immunol 2012;32:514-22.
78. Maurer B, Stanczyk J, Jungel A et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 2010;62:1733-43.
79. Sing T, Jinnin M, Yamane K et al. microRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma. Rheumatology 2012;51: 1550-6.
80. Honda N, Jinnin M, Kira-Etoh T et al. miR-150 downregulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin beta3. Am J Pathol 2013;182: 206-16.
81. Makino K, Jinnin M, Kajihara I et al. Circulating miR-142-3p levels in patients with systemic sclerosis. Clin Exp Dermatol 2012;37:34-9.
82. van Rooij E, Sutherland LB, Thatcher JE et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008;105:13027-32.
83. Honda N, Jinnin M, Kajihara I et al. TGF-beta-mediated downregulation of microRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts. J Immunol 2012;188: 3323-31.
84. Jiang X, Tsitsiou E, Herrick SE, Lindsay MA. MicroRNAsand the regulation of fibrosis. FEBS J 2010;277:2015-21.
85. Kahaleh B, Wang W. Decrease activity of DNA demethylase in SSC fibroblast and microvascular endothelial cells: a possible mechanism for persistent SSC phenotype [abstract]. Rheumatology 2012;51:ii5e6.
86. Hu B, Gharaee-Kermani M, Wu Z, Phan SH. Essential role of MeCP2 in the regulation of myofibroblast differentiation during pulmonary fibrosis. Am J Pathol 2011;178: 1500-8.
87. Fabbri M, Garzon R, Cimmino A et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007;104:15805-10.
88. Wang Z, Jinnin M, Kudo H et al. Detection of hairmicroRNAs as the novel potent biomarker: evaluation of the usefulness for the diagnosis of scleroderma. J Dermatol Sci 2013;72:134-41.
89. Wang Y, Kahaly OR, Kahaleh B. Down-regulated microRNA-152 induces aberrant DNA methylation in scleroderma endothelial cells by targeting DNA methyltransferase 1 [abstract]. Arthritis Rheum 2010; 62(Suppl 10):1352.
90. Zhu H, Luo H, Li Y et al. MicroRNA-21 in scleroderma fibrosis and its function in TGF-beta-regulated fibrosisrelated genes expression. J Clin Immunol 2013;33:1100-9.
91. Klip H, Verloop J, van Gool JD et al. Hypospadias in sons of women exposed to diethylstilbestrol in utero: a cohort study. Lancet 2002;359:1102-7.
92. Greer JM, McCombe PA. The role of epigenetic mechanisms and processes in autoimmune disorders. Biologics 2012;6:307-27.
93. Lucas A. Programming by early nutrition: an experimental approach. J Nutr 1998;128(Suppl):401S-406S.
94. Choi SW, Friso S. Epigenetics: a new bridge between nutrition and health. Adv Nutr 2010;1:8-16.
95. Johnson AB, Denko N, Barton MC. Hypoxia induces a novel signature of chromatin modifications and global repression of transcription. Mutat Res 2008;640: 174-9.
96. Chen H, Yan Y, Davidson TL, Shinkai Y, Costa M. Hypoxic stress induces dimethylated histone H3 lysine 9 through histone methyltransferase G9a in mammalian cells. Cancer Res 2006;66:9009-16.
97. Jung JE, Lee HG, Cho IH et al. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 2005;19:1296-8.
98. Herrick AL, Rieley F, Schofield D et al. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 1994; 21:1477-83.
99. Sambo P, Baroni SS, Luchetti M et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001;44: 2653-64.
100. Andersen GN, Caidahl K, Kazzam E et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 2000;43: 1085-93.
101. Ogawa F, Shimizu K, Muroi E et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology 2006; 45:815-8.
102. Svegliati S, Cancello R, Sambo P et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 2005;280: 36474-82.
103. O'Hagan HM, Wang W, Sen S et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG islands. Cancer Cell 2011;20: 606-19.
104. Zhang R, Kang KA, Kim KC et al. Oxidative stress causes epigenetic alteration of CDX1 expression in colorectal cancer cells. Gene 2013;524:214-9.
105. Lim SO, Gu JM, Kim MS et al. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the Ecadherin promoter. Gastroenterology 2008;135: 2128-40, 2140e1-8.